Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Peacock, Oliver ^a   Lee, Andrew C ^a   Cameron, Fraser ^a   Tarbox, Rebecca ^a   Vafadar Isfahani, Natasha ^a   Tufarelli, Cristina ^a   Lund, Jonathan N ^a  

^a Surgery Group Division of Medical Sciences and Graduate Entry Medicine School of Medicine   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; MICRORNA 21; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROGRAMMED CELL DEATH 4 PROTEIN; PROSTAGLANDIN E2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MESSENGER RNA; MICRORNA; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; RNA BINDING PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CARCINOMA CELL; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; ENZYME REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; ONCOGENE; PROGRAMMED CELL DEATH 4 GENE; RECTUM CANCER; TUMOR SUPPRESSOR GENE; UPREGULATION; BIOLOGICAL MODEL; CANCER GRADING; COLORECTAL NEOPLASMS; COMPLICATION; DRUG EFFECTS; GENETICS; INFLAMMATION; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84907966243     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110267     Document Type: Article

References (52)

1. Jemal A, Bray F, Center M.M., Ferlay J., Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Figueredo A, Coombes ME, Mukherjee S. (2008) Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev: CD005390.
3. UK CR (2011) Bowel Cancer Survival Statistics.
4. Walsh JM, Terdiman J.P. (2003) Colorectal cancer screening: scientific review. JAMA 289: 1288-1296.
5. Fearon ER, Vogelstein B. (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
6. Smith G, Carey FA, Beattie J, Wilkie M.J., Lightfoot TJ, et al. (2002) Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 99: 9433-9438.
7. Pisani P, Parkin DM, Munoz N, Ferlay J. (1997) Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 6: 387-400.
8. Elwood PC, Gallagher AM, Duthie G.G., Mur LA, Morgan G. (2009) Aspirin, salicylates, and cancer. Lancet 373: 1301-1309.
9. Flossmann E, Rothwell P.M. (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613.
10. Rothwell PM, Wilson M, Elwin C.E., Norrving B., Algra A, et al. (2010) Longterm effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750.
11. Rothwell PM, Price JF, Fowkes F.G., Zanchetti A., Roncaglioni MC, et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602-1612.
12. Rothwell PM, Fowkes FG, Belch J.F., Ogawa H., Warlow CP, et al. (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41.
13. Chan AT, Ogino S, Fuchs C.S. (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658.
14. Holmes MD, Chen WY, Li L, Hertzmark E., Spiegelman D, et al. (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472.
15. Leitzmann MF, Stampfer MJ, Ma J, Chan J.M., Colditz GA, et al. (2002) Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11: 1108-1111.
16. Chan AT, Ogino S, Fuchs C.S. (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142.
17. Singer, II, Kawka DW, Schloemann S, Tessner T., Riehl T, et al. (1998) Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115: 297-306.
18. Greenhough A, Smartt HJ, Moore A.E., Roberts HR, Williams AC, et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
19. Sonkoly E, Stahle M, Pivarcsi A. (2008) MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol 33: 312-315.
20. Wu F, Zikusoka M, Trindade A., Dassopoulos T, Harris ML, et al. (2008) MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 135: 1624-1635 e1624.
21. Schetter AJ, Heegaard NH, Harris C.C. (2010) Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31: 37-49.
22. Lin CJ, Gong HY, Tseng H.C., Wang WL, Wu J.L. (2008) miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 375: 315-320.
23. Lu TX, Munitz A, Rothenberg M.E. (2009) MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol 182: 4994-5002.
24. Zhang Z, Li Z, Gao C., Chen P, Chen J, et al. (2008) miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 88: 1358-1366.
25. Medina PP, Nolde M, Slack F.J. (2010) OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467: 86-90.
26. Volinia S, Calin GA, Liu C.G., Ambs S., Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
27. Asangani IA, Rasheed SA, Nikolova D.A., Leupold JH, Colburn NH, et al. (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128-2136.
28. Ludwig K, Fassan M, Mescoli C., Pizzi M, Balistreri M, et al. (2013) PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. Virchows Arch 462: 57-63.
29. Pfaffl MW (2001) A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 29: e45.
30. Bustin SA, Benes V, Garson J.A., Hellemans J., Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
31. Bhatti I, Lee A, James V., Hall RI, Lund JN, et al. (2011) Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg 15: 199-208.
32. The Royal College of Pathologists U (2007) Dataset for colorectal cancer (2nd edition).
33. Chang KH, Miller N, Kheirelseid E.A., Ingoldsby H., Hennessy E, et al. (2011) MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur J Surg Oncol.
34. Schetter AJ, Leung SY, Sohn J.J., Zanetti KA, Bowman ED, et al. (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436.
35. Slaby O, Svoboda M, Fabian P., Smerdova T, Knoflickova D, et al. (2007) Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397-402.
36. Schmid T, Bajer MM, Blees J.S., Eifler LK, Milke L, et al. (2011) Inflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation. Carcinogenesis 32: 1427-1433.
37. Kirkland SC (1985) Dome formation by a human colonic adenocarcinoma cell line (HCA-7). Cancer Res 45: 3790-3795.
38. O'Callaghan G., Kelly J, Shanahan F., Houston A. (2008) Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells. Br J Cancer 99: 502-512.
39. Zhang Z, DuBois R.N. (2001) Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 20: 4450-4456.
40. Wang P, Zou F, Zhang X., Li H, Dulak A, et al. (2009) microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 69: 8157-8165.
41. Foreman JE, Sorg JM, McGinnis K.S., Rigas B., Williams JL, et al. (2009) Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog 48: 942-952.
42. Kutchera W, Jones DA, Matsunami N, Groden J., McIntyre TM, et al. (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A 93: 4816-4820.
43. Cmarik JL, Min H, Hegamyer G., Zhan S, Kulesz-Martin M, et al. (1999) Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A 96: 14037-14042.
44. Shin VY, Jin H, Ng E.K., Cheng AS, Chong WW, et al. (2011) NF-{kappa}B targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. Carcinogenesis 32: 240-245.
45. Li M, Wu X, Xu X.C. (2001) Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7: 1010-1016.
46. Abdelrahim M, Safe S. (2005) Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 68: 317-329.
47. Yao M, Lam EC, Kelly C.R., Zhou W., Wolfe M.M. (2004) Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 90: 712-719.
48. Nagatsuka I, Yamada N, Shimizu S., Ohira M, Nishino H, et al. (2002) Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int J Cancer 100: 515-519.
49. Sheng H, Shao J, Kirkland S.C., Isakson P., Coffey RJ, et al. (1997) Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99: 2254-2259.
50. Leahy KM, Ornberg RL, Wang Y, Zweifel B.S., Koki AT, et al. (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631.
51. Masferrer JL, Leahy KM, Koki A.T., Zweifel BS, Settle SL, et al. (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311.
52. Lu L, Byrnes K, Han C., Wang Y, Wu T. (2014) MiR-21 Targets 15-PGDH and Promotes Cholangiocarcinoma Growth. Mol Cancer Res.